Shares of Abbott Laboratories plunged 10.04% to $108.61 Thursday, on what proved to be an all-around great trading session ...

The medical-products maker’s shares tumbled after its quarterly profit and sales underwhelmed investors.

In the fourth quarter, Abbott’s sales were $11.5 billion, below the average analyst estimate of $11.8 billion. Nutrition ...

Abbott shares fell after quarterly sales and early 2026 earnings guidance missed estimates, even as the company forecast ...

Abbott stock fell more than 7% in premarket trading after the company missed on Q4 revenue and gave a weaker Q1 2026 outlook, ...

Abbott Laboratories stock has reached a 52-week low, closing at $107.27. This marks a notable point for the healthcare company, as it navigates a challenging market environment. Over the past year, ...

The mixed earnings report comes on the heels of the Abbott Park, IL-based company announcing it would acquire Exact Sciences for $21 billion.

Abbott Laboratories (ABT) stock falls as underperformance in the company's Nutrition segment leads it to record lower than expected Q4 sales. Read more here.

In recent weeks, Abbott Laboratories raised its quarterly dividend for the 52nd consecutive year and secured CE Mark approval ...

Abbott received CE Mark for the TactiFlex™ Duo Ablation Catheter to treat patients with abnormal heart rhythms. Shares of Abbott fell 0.3% to close at $120.73 on Wed ...

Abbott Laboratories (ABT) on Thursday reported fourth-quarter earnings of $1.78 billion. On a per-share basis, the Abbott ...

ADJUSTED EARNINGS: Stripping out certain one-time items, earnings are forecast to come in at $1.50 a share. That compares with adjusted earnings of $1.34 a share a year earlier. REVENUE: Quarterly ...